We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Safety and efficacy of <sup>90</sup> Yttrium- Ibritumomab- Tiuxetan for untreated follicular lymphoma patients. An Italian cooperative study.
- Authors
Ibatici, Adalberto; Pica, Gian Matteo; Nati, Sandro; Vitolo, Umberto; Botto, Barbara; Ciochetto, Chiara; Petrini, Mario; Galimberti, Sara; Ciabatti, Elena; Orciuolo, Enrico; Zinzani, Pier Luigi; Cascavilla, Nicola; Guolo, Fabio; Fraternali Orcioni, Giulio; Carella, Angelo M.
- Abstract
90 Yttrium (90 Y)- Ibritumomab- Tiuxetan combines the targeting advantage of a monoclonal antibody with the radiosensitivity of Follicular Lymphoma ( FL). Previous studies showed that 90 Y- IT is safe and effective in relapsed/refractory indolent FL, irrespective of prior treatment with rituximab. This multicentre trial aimed to evaluate the safety and the efficacy of 'upfront' single-agent (90 Y)- Ibritumomab- Tiuxetan in advanced-stage FL. The primary objective was the incidence of responses in terms of complete ( CR) and partial remission ( PR). Fifty patients with stage II 'bulky', III or IV FL received a single treatment course with (90 Y)- Ibritumomab- Tiuxetan as initial therapy. The median age was 60 years. Bone marrow involvement (<25%) was observed in 24 patients (48%) and 7 (14%) had an elevated lactate dehydrogenase level. The overall response ( ORR) and CR rates were 94% and 86%, respectively with a median follow-up of 38·8 months. The median progression-free survival ( PFS) was not reached, whereas the 3-year estimated PFS and overall survival ( OS) rate was 63·4% and 90%, respectively. Grade 3/4 neutropenia and thrombocytopenia occurred in 30% and 26% of patients respectively; none experienced grade 3/4 non-haematological toxicity. No cases of secondary haematological malignancies were observed. (90 Y)- Ibritumomab- Tiuxetan was demonstrated to be highly effective and safe as first-line treatment for advanced-stage FL.
- Subjects
LYMPHOMAS; MONOCLONAL antibodies; LACTATE dehydrogenase; RITUXIMAB; YTTRIUM; THROMBOCYTOPENIA; NEUTROPENIA
- Publication
British Journal of Haematology, 2014, Vol 164, Issue 5, p710
- ISSN
0007-1048
- Publication type
Article
- DOI
10.1111/bjh.12695